Unimark Remedies Ltd is a USFDA and EUGMP approved facility that manufactures Active Pharmaceutical Ingredients (APIs) including various high-quality products such as Tigecycline, Lisinopril, Montelukast, Nitrofurantoin, Nalidixic Acid, Flecainide, Moxifloxacin, and Carbapenems. With a strategic management change leading to 100% ownership by the Shamrock Pharma Group, the company has recently upgraded its facilities to enhance quality standards, achieving a world-class API manufacturing capability with a combined capacity of 350 KL. Their manufacturing facilities have also received certifications from various regulatory authorities, including the US FDA, MHRA, EDQM, COFEPRIS, TGA, WHO, and other Ministries of Health.

Services include:
- Biologics
- Manufacturing of APIs
- Compliance with global quality standards

Unimark Remedies Ltd is dedicated to delivering high-quality pharmaceutical products while maintaining compliance with rigorous international standards. For more information, please visit unimarkremedies.com.